{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Tumor+Mutation+Burden", "query": { "condition": "High Tumor Mutation Burden" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T23:45:09.787Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05199272", "title": "A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Neuroendocrine Tumors", "MSI-H Cancer", "Cancer With A High Tumor Mutational Burden", "Extensive-stage Small-cell Lung Cancer" ], "interventions": [ { "name": "23ME-00610", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "23andMe, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 141, "start_date": "2021-12-29", "completion_date": "2025-03", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-05-21T23:45:09.787Z", "location_count": 10, "location_summary": "Palo Alto, California • Atlanta, Georgia • Detroit, Michigan + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05199272" }, { "nct_id": "NCT06270706", "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumor" ], "interventions": [ { "name": "PLN-101095", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pliant Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2023-08-30", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-05-21T23:45:09.787Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06270706" }, { "nct_id": "NCT04098068", "title": "Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Tumor Mutation Burden", "High TMB (Tumor Mutation Burden)", "MSS (Microsatellite Stable)" ], "interventions": [ { "name": "MK-3475", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2018-01-25", "completion_date": "2025-02-05", "has_results": true, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-05-21T23:45:09.787Z", "location_count": 3, "location_summary": "Baltimore, Maryland • New York, New York • Columbus, Ohio", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04098068" }, { "nct_id": "NCT02635672", "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "VIP152 (BAY 1251152)", "type": "DRUG" }, { "name": "VIP152 (BAY 1251152) 30 mg", "type": "DRUG" }, { "name": "Keytruda", "type": "DRUG" }, { "name": "VIP152 (BAY 1251152) 15 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vincerx Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2016-02-10", "completion_date": "2024-11-11", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-05-21T23:45:09.787Z", "location_count": 13, "location_summary": "Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02635672" }, { "nct_id": "NCT03668119", "title": "A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pan Tumor" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 212, "start_date": "2018-10-31", "completion_date": "2023-08-02", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-05-21T23:45:09.787Z", "location_count": 10, "location_summary": "Santa Monica, California • Denver, Colorado • Minneapolis, Minnesota + 7 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Johnson City", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03668119" }, { "nct_id": "NCT07362225", "title": "MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Polycythemia Vera", "ET (Essential Thrombocythemia)", "Polycythemia Vera (PV)", "Essential Thrombocythemia (ET)", "Primary Myelofibrosis (MF)", "Primary Myelofibrosis (PMF)", "Myelofibrosis", "Myelofibrosis (MF)", "Myelofibrosis, Primary", "Myelofibrosis, Post ET", "Myelofibrosis, Post PV", "Myelofibrosis (PMF)", "Myelofibrosis，MF", "Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis", "Myelofibrosis Due to and Following Polycythemia Vera", "Myelofibrosis Transformation in Essential Thrombocythemia", "Myelofibrosis With High Molecular Risk Mutations", "MF", "Secondary Myelofibrosis", "Secondary Myelofibrosis in Myeloproliferative Disease", "Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)", "Post-Polycythemia Vera Myelofibrosis", "Post-polycythemia Vera Myelofibrosis (PPV-MF)", "Post-polycythemia Vera Myelofibrosis (Post-PV MF)", "Post-polycythemia Vera Myelofibrosis(Post-PV MF)", "Post-PV MF", "Post-Essential Thrombocythemia Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis (PET-MF)", "Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)", "Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)", "Post-ET MF", "Pre-fibrotic Myelofibrosis", "Myeloproliferative Disorder", "Myeloproliferative Disorders", "Myeloproliferative Disorders (MPD)", "Myeloproliferative Neoplasms (MPNs)", "Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis", "Myeloproliferative Neoplasm With 10% Blasts or Higher", "Myeloproliferative Neoplasms", "MPN", "MPN (Myeloproliferative Neoplasms)", "MPN-associated Myelofibrosis", "Myeloproliferative Neoplasm, Unclassifiable", "Myeloproliferative Neoplasm, Not Otherwise Specified", "Accelerated Phase MPN", "Accelerated Phase Myeloproliferative Neoplasm", "Blast Phase MPN", "Blast Phase Myeloproliferative Neoplasm", "Thrombocythemia Myelofibrosis (PET-MF)", "Thrombocythemia, Essential", "Thrombocythemia, Hemorrhagic", "Agnogenic Myeloid Metaplasia", "Chronic Idiopathic Myelofibrosis", "Idiopathic Myelofibrosis", "MDS/MPN Crossover Syndromes" ], "interventions": [], "intervention_types": [], "sponsor": "MPN Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2025-09-26", "completion_date": "2035-09-08", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-05-21T23:45:09.787Z", "location_count": 2, "location_summary": "Chicago, Illinois • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07362225" }, { "nct_id": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Unresectable Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Triple Negative Breast Cancer", "Non-Small Cell Lung Cancer Squamous", "Non-Small Cell Lung Cancer Non-squamous", "Colorectal Cancer (MSI-H)", "Gastric Cancer", "Cervical Cancer", "Basal Cell Carcinoma", "Bladder Cancer", "Merkel Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Cutaneous Squamous Cell Carcinoma", "Pleural Mesothelioma", "Esophageal Cancer", "Endometrial Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "MSI-H Solid Malignant Tumor", "Cancer With A High Tumor Mutational Burden", "Epithelial Ovarian Carcinoma", "Primary Peritoneal Cancer", "Gastroesophageal Junction (GEJ) Cancer", "Acral Melanoma", "Mucosal Melanoma", "Cutaneous Melanoma", "DMMR Solid Malignant Tumor", "Fallopian Tube Cancer", "Ovarian Cancer", "MSI-H Cancer", "DMMR Cancer", "Pancreas Adenocarcinoma (MSI-H)", "Skin Cancer", "Viral Cancer", "Cervical Cancers", "Endometrial Cancer" ], "interventions": [ { "name": "MDNA11", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medicenna Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2021-08-27", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-05-21T23:45:09.787Z", "location_count": 7, "location_summary": "San Diego, California • San Francisco, California • Santa Monica, California + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05086692" }, { "nct_id": "NCT06634875", "title": "Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "isunakinra", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Buzzard Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-01-30", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-05-21T23:45:09.787Z", "location_count": 2, "location_summary": "Los Angeles, California • Newport Beach, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06634875" }, { "nct_id": "NCT03236935", "title": "Phase Ib of L-NMMA and Pembrolizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Malignant Melanoma", "Head and Neck Squamous Cell Carcinoma", "Classical Hodgkin Lymphoma", "Urothelial Carcinoma Bladder", "DNA Repair-Deficiency Disorders" ], "interventions": [ { "name": "L-NMMA", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2018-08-27", "completion_date": "2022-04-22", "has_results": true, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-05-21T23:45:09.787Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03236935" }, { "nct_id": "NCT05592626", "title": "A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Genital Neoplasm, Female", "Urogenital Neoplasms", "Lung Neoplasm", "Neoplasms by Site", "Papillomavirus Infection", "Epstein-Barr Virus Infections", "Carcinoma", "Neoplasms", "Vulvar Neoplasms", "Vulvar Diseases", "Abdominal Neoplasm" ], "interventions": [ { "name": "STAR0602", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marengo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 365, "start_date": "2023-01-04", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-05-21T23:45:09.787Z", "location_count": 18, "location_summary": "Loma Linda, California • Sacramento, California • Denver, Colorado + 14 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Celebration", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05592626" } ] }